文献速递血栓与止血

艾美赛珠单抗与免疫抑制治疗用于获得性血友病A管理的比较

Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A.
PubMed 文献 · J Thromb Haemost · 2024-06-25

本研究通过倾向性评分匹配比较两项研究,对比获得性血友病A(AHA)诊断后早期使用艾美赛珠单抗预防(GTH-AHA-EMI,N=47)与免疫抑制治疗(IST;GTH-AH 01/2010,N=101)的结局。主要终点为前12周临床相关新发出血率,艾美赛珠单抗组较IST组降低68%(发生比0.325;95%CI,0.182-0.581)。艾美赛珠单抗组24周总生存率更优(90% vs 76%;HR,0.44;95%CI,0.24-0.81)。

要点

  • AHA诊断后早期使用艾美赛珠单抗较IST降低前12周临床相关新发出血率68%。
  • 前12周感染总频率两组无差异,但艾美赛珠单抗组感染致死比例低于IST组。
  • 艾美赛珠单抗组24周总生存率优于IST组(90% vs 76%;HR,0.44)。

核心结论

  • AHA初诊后早期使用艾美赛珠单抗替代IST可减少出血和致死性感染并改善总生存。

研究设计与样本

  • 比较两项研究:IST研究GTH-AH 01/2010(N=101)与艾美赛珠单抗预防研究GTH-AHA-EMI(N=47)。
  • 使用倾向性评分匹配平衡基线特征。
  • 主要终点为前12周临床相关新发出血率;次要终点为不良事件和总生存。

主要发现

  • 基于负二项模型,艾美赛珠单抗组出血率较IST组降低68%(发生比0.325;95%CI,0.182-0.581)。
  • 前12周感染总频率:艾美赛珠单抗组21% vs IST组29%,未见明显差异。
  • 感染致死比例:艾美赛珠单抗组0% vs IST组11%。
  • 血栓栓塞事件:艾美赛珠单抗组2% vs IST组7%。
  • 24周总生存率:艾美赛珠单抗组90% vs IST组76%(HR,0.44;95%CI,0.24-0.81)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) is standard of care to eradicate autoantibody production and protect from further bleeding but carries a risk of severe infection and mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential to reduce the need for early and aggressive IST. OBJECTIVES: To compare outcomes of 2 studies that used either IST (GTH-AH 01/2010; N = 101) or prophylaxis with emicizumab (GTH-AHA-EMI; N = 47) early after diagnosis of AHA. METHODS: Baseline characteristics were balanced by propensity score matching. Primary endpoint was the rate of clinically relevant new bleeds during the first 12 weeks; secondary endpoints were adverse events and overall survival. RESULTS: The negative binominal model-based bleeding rate was 68% lower with emicizumab as compared with IST (incident rate ratio, 0.325; 95% CI, 0.182-0.581). No difference was apparent in the overall frequency of infections (emicizumab 21%, IST 29%) during the first 12 weeks, but infections were less often fatal in emicizumab-treated patients (0%) compared with IST-treated patients (11%). Thromboembolic events occurred less often with emicizumab (2%) than with IST (7%). Overall survival after 24 weeks was better with emicizumab (90% vs 76%; hazard ratio, 0.44; 95%, CI, 0.24-0.81). CONCLUSION: Using emicizumab instead of IST in the early phase after initial diagnosis of AHA reduced bleeding and fatal infections and improved overall survival.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hart C, Klamroth R, Sachs UJ, et al. Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A. J Thromb Haemost. 2024. PMID: 38936699. doi:10.1016/j.jtha.2024.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。